IBEX 35
10.700,30 -64,70 (-0,60%) Euro Stoxx 50
4.920,23 -16,34 (-0,33%) Dólar/Euro
1,0662 +0,0016 (+0,15%) Petróleo Brent
86,51 -0,60 (-0,69%) Oro
2.394,50 -3,50 (-0,15%) Bitcoin EUR
61.272,61 +2.751,94 (+4,70%)
Royalty Pharma plc (RPRX)
Antes de la apertura:
Royalty Pharma plc
110 East 59th Street
New York, NY 10022
United States
212 883 0200
https://www.royaltypharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Pablo Gerardo Legorreta | Founder, Chairman of the Board & CEO | N/A | N/A | 1965 |
| Mr. Terrance P. Coyne | Executive VP & CFO | 4,35M | N/A | N/A |
| Mr. George Wingate Lloyd | Executive VP of Investments & Chief Legal Officer | 4,35M | N/A | 1960 |
| Mr. Christopher Hite | Vice Chairman & Executive VP | 4,35M | N/A | 1967 |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive VP and Head of Research & Investments | 4,35M | N/A | N/A |
| Mr. Arthur Richard McGivern J.D. | Executive Vice President of Investments & General Counsel | N/A | N/A | N/A |
| Mr. Ashwin Pai M.D. | Executive Vice President of Investments | N/A | N/A | N/A |
| Ms. Kristin Stafford | Senior VP & Chief Accounting Officer | N/A | N/A | 1983 |
| Mr. Eric Cornelius Schneider | Senior VP & Chief Technology Officer | N/A | N/A | N/A |
| Dr. James Folmar Reddoch Ph.D. | Executive VP of Investments & Chief Scientific Officer | 3,4M | N/A | 1970 |
Descripción
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Gobierno corporativo
El ISS Governance QualityScore de Royalty Pharma plc, a día 1 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 5; Tablero: 5; Derechos de los accionistas: 6; Compensación: 3.
